Monitor Q4 2026 for BP-205 MAD study data readout, which is the next major pipeline catalyst. The CEO transition is orderly and well-flagged, so no near-term disruption is expected.
Price Chart
Executive Summary
Harmony Biosciences announced a planned CEO transition: current CEO Jeffrey Dayno will retire on December 31, 2026, and COO Peter Anastasiou will become President and CEO effective January 1, 2027. The company reiterated its full-year 2026 WAKIX net revenue guidance of $1.0B-$1.04B and remains on track for BP-205 MAD study data in Q4 2026. This is a routine, orderly succession with no financial surprises or operational disruption.
Key Facts
- CEO Jeffrey Dayno retiring effective Dec 31, 2026; will serve as non-executive advisor through 2027
- COO Peter Anastasiou appointed President and CEO effective Jan 1, 2027, and appointed to the Board
- Full-year 2026 WAKIX net revenue guidance reiterated at $1.0B to $1.04B
- Company on track to report BP-205 multiple ascending dose (MAD) study data in Q4 2026
- Succession described as part of Board's planned leadership succession plan
Financial Impact
No financial impact from the transition itself; revenue guidance unchanged at $1.0B-$1.04B
Risk Factors
- Execution risk during leadership transition, though Anastasiou is an internal hire with prior board experience
- BP-205 data readout in Q4 2026 carries binary outcome risk for pipeline valuation
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-115282 |
| Document: hrmy-ex99d1.htm | 0001104659-26-115282 |
| Document: 0001104659-26-115282-index-headers.html | 0001104659-26-115282 |
| Document: 0001104659-26-115282-index.html | 0001104659-26-115282 |
| Document: 0001104659-26-115282.txt | 0001104659-26-115282 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G/A | $36.90 | awaiting T+20 | awaiting T+20 | $37.95 (+2.85%) |
Oct 13, 2026 14d ago | 8-K | $37.03 | awaiting T+20 | awaiting T+20 | $37.95 (+2.48%) |
Oct 1, 2026 26d ago | Press Release | $39.57 | awaiting T+20 | awaiting T+20 | $37.95 (−4.09%) |
Aug 4, 2026 12w ago | 8-K | $38.78 | awaiting T+20 | awaiting T+20 | $37.95 (−2.14%) |
Aug 4, 2026 12w ago | Press Release | $38.78 | awaiting T+20 | awaiting T+20 | $37.95 (−2.14%) |
Jul 16, 2026 14w ago | 8-K | $33.53 $38.50 | ▲ +14.82% | ▲ +11.20% | $37.95 (+13.18%) |
Jun 30, 2026 17w ago | 144 | $36.00 $35.86 | ▲ +0.39% | ▼ −1.80% | $37.95 (−5.42%) |
Jun 24, 2026 17w ago | 144 | $34.13 $35.80 | ▼ −4.89% | ▼ −4.36% | $37.95 (−11.19%) |
Jun 9, 2026 20w ago | 144 | $35.48 $38.21 | ▲ +7.69% | ▲ +4.07% | $37.95 (+6.96%) |
Jun 5, 2026 20w ago | 144 | $32.39 $37.01 | ▲ +14.26% | ▲ +12.63% | $37.95 (+17.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers